caa a22 4500 60549116X CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10147-014-0775-2 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0775-2 Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma [Elektronische Daten] [Yoichi Fujii, Masaomi Ikeda, Kazuhiro Kurosawa, Mariko Tabata, Takayuki Kamigaito, Chihiro Hosoda, Toshikazu Okaneya] Background: To evaluate the clinicopathological features and identify predictive factors in patients with early and late recurrence following initial surgery for localized renal cell carcinoma. Methods: From April 1988 to January 2013, 486 patients without metastases at the initial diagnosis underwent either radical nephrectomy or partial nephrectomy and were followed up thereafter. Patients were divided into 3 groups; no recurrence, early recurrence (recurrence within 5years), and late recurrence (recurrence after 5years). Cancer-specific survival after recurrence was analyzed by using the Kaplan-Meier method. Multivariate logistic regression analysis was applied to define clinical and pathological factors correlated to early and late recurrence following surgery. Results: Seventy-seven (15.8%) and 18 (3.7%) patients developed early and late recurrence, respectively. In multivariate logistic regression analysis, positive symptoms at diagnosis,≥pT2, positive lymphovascular invasion, and grade 3 were independent predictive factors for early recurrence. Age at surgery and≥pT2 were significantly correlated to late recurrence. The 5-year cancer-specific survival rate after recurrence was 72.4 and 52.9% in the late and the early recurrence groups, respectively (P=0.044). Conclusions: The risk factors for clinical recurrence differed according to the time that had elapsed between initial surgery and the first metastasis in patients with localized renal cell carcinoma. Our study showed age at initial surgery and the pT stage were independent predictive factors for late recurrence. Further investigation of a larger number of patients is required to predict which patients may develop recurrence in the future and to choose appropriate treatment. Japan Society of Clinical Oncology, 2014 Renal cell carcinoma nationallicence Late recurrence nationallicence Predictive factor nationallicence Surgery nationallicence Nephrectomy nationallicence Fujii Yoichi Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Ikeda Masaomi Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Kurosawa Kazuhiro Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Tabata Mariko Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Kamigaito Takayuki Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Hosoda Chihiro Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut Okaneya Toshikazu Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 802-807 1341-9625 20:4<802 2015 20 10147 https://doi.org/10.1007/s10147-014-0775-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0775-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fujii Yoichi Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Ikeda Masaomi Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Kurosawa Kazuhiro Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Tabata Mariko Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Kamigaito Takayuki Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Hosoda Chihiro Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 700 1- Okaneya Toshikazu Department of Urology, Toranomon Hospital, 2-2-2 Toranomon, 105-8470, Minato-Ku, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 802-807 1341-9625 20:4<802 2015 20 10147